27. New Technologies for the Pharmacokinetic Improvement of Coagulation Factor Proteins

  1. Emérito-Carlos Rodríguez-Merchán MD, PHD1,2 and
  2. Leonard A. Valentino MD3
  1. Leonard A. Valentino MD

Published Online: 12 MAY 2011

DOI: 10.1002/9781119979401.ch27

Current and Future Issues in Hemophilia Care

Current and Future Issues in Hemophilia Care

How to Cite

Valentino, L. A. (2011) New Technologies for the Pharmacokinetic Improvement of Coagulation Factor Proteins, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodríguez-Merchán and L. A. Valentino), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119979401.ch27

Editor Information

  1. 1

    Department of Orthopedic Surgery and Hemophilia Unit, La Paz University Hospital, Spain

  2. 2

    School of Medicine, Autonomous University, Madrid, Spain

  3. 3

    Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Author Information

  1. Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Publication History

  1. Published Online: 12 MAY 2011
  2. Published Print: 13 MAY 2011

ISBN Information

Print ISBN: 9780470670576

Online ISBN: 9781119979401

SEARCH

Keywords:

  • factor IX;
  • factor VIII;
  • hemophilia A;
  • hemophilia B;
  • pharmacokinetics;
  • pharmacodynamics

Summary

Clotting factor replacement therapy, while highly effective in controlling bleeding in patients with hemophilia, is hampered by the formation of inhibitory antibodies and a relatively short duration of hemostatic activity. An important focus of current hemophilia research is the development of less immunogenic and more potent and/or longer-acting factor concentrates.